About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Continuous infusions of ceftazidime for pulmonary exacerbations were found to be safe and effective, with the potential to reduce the costs of therapy, enhance patients’ quality of life, and eradicate resistant isolates of Pseudomonas aeruginosa.
William A. Prescott, Jr., PharmD; Allison E. Gentile, PharmD; Jerod L. Nagel, PharmD; and Rebecca S. Pettit, PharmD, MBA, BCPS
Causes, Impact, and Management Strategies
The U.S. is experiencing a severe shortage of drugs, especially intravenous cancer medications. The author reviews the causes of these shortages; the effects on physicians, hospitals, and patients; the FDA’s role in managing the shortages; and strategies for alleviating the crisis.
C. Lee Ventola, MS
$1 Billion Is Available to Fight Medical Errors and Reduce Readmissions
Two programs are expected to offer $1 billion in grants over a period of 5 years to hospitals and community partners in an effort to reduce patient readmissions and errors in facilities—if funds are not cut.
Patients with psoriasis and nail psoriasis can often benefit from therapies that may include biologic agents, phototherapy, and vitamin D.
Takaharu Kato and Peter Sonnenreich, MA
Changes in routines often raise the potential for mistakes.
Matthew Grissinger, RPh, FASCP
The American Hospital Association would like to expand the Section 340B drug purchase program as a way to stretch its limited resources.
FDA approvals, drug indications, and updates
Crizotinib (Xalkori) for lung cancer; tapendatol (Nucynta) extended-release tablets for moderate-to-severe pain; and eculizumab (Soliris) for atypical hemolytic uremic syndrome
Marvin M. Goldenberg, PhD, RPh, MS